182 related articles for article (PubMed ID: 28073129)
1. Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2017 Jun; 125(6):360-364. PubMed ID: 28073129
[No Abstract] [Full Text] [Related]
2. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
3. Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
Krysiak R; Okrzesik J; Okopien B
Exp Clin Endocrinol Diabetes; 2015 Oct; 123(9):561-6. PubMed ID: 26372847
[TBL] [Abstract][Full Text] [Related]
4. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
Krysiak R; Okrzesik J; Okopien B
Endocrine; 2015 May; 49(1):242-9. PubMed ID: 25239203
[TBL] [Abstract][Full Text] [Related]
5. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia.
Krysiak R; Kowalcze K; Szkrobka W; Okopien B
Eur J Intern Med; 2016 May; 30():94-98. PubMed ID: 26858210
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
8. Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine.
Krysiak R; Okopień B
Am J Ther; 2019; 26(4):e433-e440. PubMed ID: 29746287
[TBL] [Abstract][Full Text] [Related]
9. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
10. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):22-28. PubMed ID: 31234219
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
13. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
16. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
17. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
18. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
[TBL] [Abstract][Full Text] [Related]
19. Sex-Dependent Effect of Metformin on Serum Prolactin Levels In Hyperprolactinemic Patients With Type 2 Diabetes: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2018 Jun; 126(6):342-348. PubMed ID: 29169197
[TBL] [Abstract][Full Text] [Related]
20. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]